VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

NCT01289210 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped The study was stopped due to slow rate of recruitment.

Conditions

Low Grade B Cell Lymphoma

Interventions

DRUG: VTX-2337 plus radiotherapy

Sponsor

Celgene

Collaborators

[object Object]